RAIN

Rain Oncology Inc. Common Stock

RAIN

Market cap $44M

Delisted

RAIN was delisted on the 25th of January, 2024.

Back to rankings

About: Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Employees: 63

Healthcare Drug Manufacturers - General

Financial journalist opinion

RAIN ENHANCEMENT TECHNOLOGIES HOLDCO, INC. RECEIVES AND APPEALS NASDAQ DELISTING NOTICE

NAPLES, FL, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Rain Enhancement Technologies Holdco, Inc. (Nasdaq: RAIN) (the “Company”) announced today that it received a notice (the “Notice”) on August 19, 2025 from the Listing Qualifications Staff (“Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has not regained compliance with Nasdaq Listing Rule 5450(b)(2)(A), requiring the Company to maintain a market value of listed securities of at least $50 million, and Nasdaq Listing Rule 5450(b)(2)(B), requiring the Company to maintain a market value of publicly held shares of at least $15 million. The Notice provides that the Company has until 4:00 p.m. Eastern Time on August 26, 2025 to appeal the Staff's delisting determination.

RAIN ENHANCEMENT TECHNOLOGIES HOLDCO, INC. RECEIVES AND APPEALS NASDAQ DELISTING NOTICE

Rain Enhancement Technologies Announces Fog Mitigation Pilot in Australia

Company Expands WETA Platform Applications Beyond Rainfall Generation to Address Multi-Billion Dollar Fog Impact on Global Transportation and Industry NAPLES, FL / ACCESS Newswire / August 20, 2025 / Rain Enhancement Technologies Holdco, Inc. (NASDAQ:RAIN) ("RET" or the "Company"), a leading provider of ionization rainfall generation technology, today announced plans to conduct its first fog mitigation pilot in Australia this month, weather permitting. This groundbreaking initiative marks RET's expansion of its Weather Enhancement Technology Array (WETA) platform beyond rainfall generation to address the significant economic impact of fog on transportation, agriculture, manufacturing, and energy production worldwide.

Rain Enhancement Technologies Announces Fog Mitigation Pilot in Australia

Rain Enhancement Technologies Strengthens Board of Directors with Appointment of Industry Veterans Bob Reardon and Marc Peperzak

Insurance and Agriculture Leaders Bring Decades of Experience in Key Target Markets for Rainfall Generation Technology NAPLES, FL / ACCESS Newswire / August 12, 2025 / Rain Enhancement Technologies Holdco, Inc. (NASDAQ:RAIN) ("RET" or the "Company"), a leading provider of ionization rainfall generation technology, today announced that Bob Reardon, Chief Executive Officer of ISG, and Marc Peperzak, Chairman and Founder of Aurora Organic Dairy, have joined the Company's Board of Directors. These strategic appointments bring deep expertise in the insurance and agriculture sectors, two critical target markets for RET's weather enhancement solutions.

Rain Enhancement Technologies Strengthens Board of Directors with Appointment of Industry Veterans Bob Reardon and Marc Peperzak

Rain Enhancement Technologies Announces Appointment of Scott Morris as Senior Technical Advisor

Veteran Engineer Brings Over 20 Years of Experience and Deep WETA Platform Expertise To Advisory Role NAPLES, FL / ACCESS Newswire / August 7, 2025 / Rain Enhancement Technologies Holdco, Inc. (NASDAQ:RAIN) ("RET" or the "Company"), a leading provider of ionization rainfall generation technology, today announced the appointment of Scott Morris as Senior Technical Advisor of Rain Enhancement Technologies, Inc., the Company's wholly-owned subsidiary. This newly created position recognizes the Company's commitment to advancing its Weather Enhancement Technology Array (WETA) platform and scaling its rainfall generation solutions globally.

Rain Enhancement Technologies Announces Appointment of Scott Morris as Senior Technical Advisor

Rain Enhancement Technologies Holdco, Inc. Announces Management Updates and Appointment of Randy Seidl as Chief Executive Officer

NAPLES, Fla.--(BUSINESS WIRE)--Rain Enhancement Technologies Holdco, Inc. (“RET Holdco” or the “Company”) (Nasdaq: RAIN, RAINW), an emerging company developing rainfall generation technology, today announced that Randy Seidl has been appointed as Chief Executive Officer (“CEO”) of RET Holdco and of its wholly-owned subsidiary, Rain Enhancement Technologies, Inc. (“RET”). Seidl has served as Co-Chief Executive Officer and a member of the Board of Directors since January 2, 2025. Seidl brings ove.

Rain Enhancement Technologies Holdco, Inc. Announces Management Updates and Appointment of Randy Seidl as Chief Executive Officer

Pathos AI Completes Acquisition of Rain Oncology

CHICAGO--(BUSINESS WIRE)--Pathos AI, Inc. (“Pathos”) today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to acquire all outstanding shares of the common stock of Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”) for $1.16 per share in cash plus one contingent value right per share (each, a “CVR”), which CVR shall represent the right to receive potential payments pursuant to the terms and subject to the conditions.

Pathos AI Completes Acquisition of Rain Oncology

RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Rain Oncology Inc. (NasdaqGS: RAIN) to Pathos AI, Inc. Under the terms of the proposed transaction, shareholders of Rain will receive $1.16 in cash plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17, for each share of Rain that they own. KSF is seeking to deter.

RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN

RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Rain Oncology Inc. (NasdaqGS: RAIN) to Pathos AI, Inc. Under the terms of the proposed transaction, shareholders of Rain will receive $1.16 in cash plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17, for each share of Rain that they own. KSF is seeking to deter.

RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN

Shareholder Alert: Ademi LLP investigates whether Rain Oncology Inc. has obtained a Fair Price in its transaction with Pathos

MILWAUKEE , Dec. 14, 2023 /PRNewswire/ -- Ademi LLP is investigating Rain (NASDAQ: RAIN) for possible breaches of fiduciary duty and other violations of law in its transaction with Pathos. Click here to learn how to join the https://www.ademilaw.com/case/rain-oncology-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Rain Oncology Inc. has obtained a Fair Price in its transaction with Pathos

RAIN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Rain Oncology Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Rain Oncology Inc. (NASDAQ: RAIN) to Pathos AI, Inc. for $1.16 in cash per share plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17 per share is fair to Rain shareholders. Halper Sadeh encourages Rain shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060.

RAIN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Rain Oncology Inc. Is Fair to Shareholders

See News Rankings

Charts implemented using Lightweight Charts™